AKT1 and glioblastoma: Furthermore, the treatment of KP-N-SI9s with Perampanel (200 μM for 48 hours), a non-competitive AMPAR antagonist that is used to control epileptic seizures, suppressed the proliferation of glioblastoma cells, via inhibiting the AKT/ERK signaling (Figure 3).